MiniMed vs Insulet
MMED and PODD side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MMED and PODD compare
Insulet is the larger company, worth 2.0 times as much as MiniMed ($10.4B against $5.1B).
Insulet grew revenue faster over the last twelve months (29.4% versus 14.3% for MiniMed).
Insulet keeps more of each dollar of sales as profit, with a net margin of 12.3% compared with −10.7% at MiniMed.
Insulet scores higher on the StockData Score (20 against 13 for MiniMed), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MMED | PODD |
|---|---|---|
| Size and price | ||
| Market cap | $5.1B | $10.4B |
| Share price | $18.28 | $149.68 |
| Change, 1 year | – | −52.7% |
| Change, 5 years | – | −51.4% |
| Beta (5Y) | – | 0.88 |
| Employees | 8,000 | 5,400 |
| StockData Score | ||
| Total score | 13 | 20 (better) |
| Valuation score | 3 | 4 (better) |
| Growth score | 2 | 5 (better) |
| Performance score | 2 | 6 (better) |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 28.0× |
| P/S | 1.7× (better) | 3.4× |
| P/B | 1.4× (better) | 7.3× |
| EV/EBITDA | – | 17.5× |
| P/FCF | – | 35.3× |
| PEG | – | 0.10 |
| FCF yield | −8.2% | 2.8% (better) |
| Fair value | $35.17 | $243.94 |
| Margin of safety | 48.0% (better) | 38.6% |
| Growth | ||
| Revenue growth (TTM) | 14.3% | 29.4% (better) |
| Revenue growth, 5Y average | – | 24.5% |
| Net income growth (TTM) | – | 59.0% |
| EPS growth (TTM) | – | 64.1% |
| EPS growth, 5Y average | – | 103% |
| Profitability | ||
| Gross margin | 54.2% | 71.1% (better) |
| Operating margin | −6.1% | 16.9% (better) |
| Net margin | −10.7% | 12.3% (better) |
| FCF margin | −13.5% | 9.6% (better) |
| Return on equity | −9.6% | 26.0% (better) |
| Return on invested capital | −4.5% | 21.9% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.67 (better) |
| Net debt / EBITDA | – | 0.67 |
| Interest coverage | – | 8.8× |
| Current ratio | 1.81 | 2.48 (better) |
| Altman Z-score | 3.46 | 5.70 (better) |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 3.2% |
| Shareholder yield | 0.00% | 3.2% (better) |
| Ownership | ||
| Held by institutions | 13.2% | 103% |
| Held by insiders | 90.6% | 0.48% |
| Insider net buying, 12 months | – | $2.3M |
| Short interest, % of float | – | 7.8% |
Go deeper
- MMED stock overview
- MMED income statement
- MMED valuation and score
- PODD stock overview
- PODD income statement
- PODD valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.